The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting…
MARKET OUTLOOK COPD is a progressive inflammatory respiratory tract and lung disease characterized by airflow obstruction and decreased lung function. The COPD market continues to suffer from…
Amyloidosis is caused by the deposition of insoluble amyloid fibrils formed by the accumulation of misfolded proteins into affected organs. Amyloid immunoglobulin light chain (AL), amyloid A (AA),…
Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
Five TNF inhibitors, five biologics with alternative mechanisms of action, and two JAK inhibitors are approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy,…
Five TNF inhibitors, five biologics with alternative mechanisms of action, and two JAK inhibitors are approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy,…
Market Outlook The asthma market in the EU5 is highly competitive. A large number of approved agents are available including maintenance therapies—LABA/ICSFDC (e.g., GSK’s Seretide and Relvar…
MARKET OUTLOOK Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as…
MARKET OUTLOOK Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as…
Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS)…
Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS)…
The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe patient population, who cannot be adequately controlled with topical agents…
MARKET OUTLOOK Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the…
MARKET OUTLOOK Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…